CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Between 54-87% of retail CFD accounts lose money. Based on 69 brokers who display this data. *Availability subject to regulation.
The cannabis industry has been receiving a significant amount of interest as more countries look to legalise the use of medical marijuana. Various research reports expect global spending on legal marijuana to increase by as much as 230% to just over $31bn in 2022 (from $9.5bn in 2017), and is then set to double to $66.3bn by 2025.
The list of countries set to legalise cannabis for medical purposes keeps growing, with the UK, South Africa and Thailand, to name a few, currently deliberating on the merits of relaxing their marijuana laws.
Meanwhile, countries including the United States, Colombia, Jamaica and Spain are tipped to follow in Canada’s footsteps and fully legalise the drug for recreational use – which will further fuel the industry’s rapid expansion.
As it stands, Canada’s marijuana market is worth an estimated $5bn, with a Deloitte paper forecasting this could jump to over $20bn as the industry matures, although this may be on the slightly optimistic side.
Companies like Canada-based Aurora Cannabis, which is recognised as leading the way in legal cannabis production, are continuing to deliver healthy results.
Aurora saw its net cannabis revenue increase by 61% sequentially to $94.6m for the fourth quarter ending 30 June 2019.
Its stock opened at CAD $0.030 in May 2014 and has since seen highs of CAD $13.70 in October 2018, before levelling out to just under CAD $5.00 this month.
While its Q4 results were lower than expected, mainly in part to previous overinflated predictions by the company, Aurora remains adamant the market provides ample opportunities for cannabis producers to branch out into other areas that will appeal to a wider audience, such as high-margin edible products like chocolates and baked goods.
Medical marijuana is becoming increasingly recognised as a legitimate pharmaceutical product, as evidence over its benefits mounts. The drug is being used to help treat and ease the symptoms associated with a plethora of serious medical conditions including cancer, Alzheimer’s, Parkinson’s disease, multiple sclerosis, epilepsy, as well as a myriad of other health problems such as anxiety, nausea and muscle spasms.
In a survey of over 1,300 US cannabis consumers, published by the medical journal Jama Internal Medicine, around 80% of respondents said they had used marijuana as a substitute for pharmaceuticals, primarily opioids.
Big pharmaceuticals appear to be aware of the threat legal cannabis is posing to their trillion-dollar industry, with a number of pharmas now eyeing up the sector for a possible takeover.
For example, GW Pharmaceuticals, which has a market cap of over $4bn, has registered around 40 cannabinoid clinical trials with the FDA, while French-based pharma Sanofi, which is valued at over $110bn, has registered around 38 cannabis-based trials as of June 2018.
Furthermore, the earnings countries can generate from cannabis via government taxation is likely to be another incentive for its widespread legalisation.
Investing in cannabis stocks such as Aurora or GW Pharmaceuticals is pretty easy, particularly if you have an account with a platform such as eToro.
The added benefit with using a platform is that it is regulated and therefore offers an element of protection to its customers – although that doesn’t mean that you can get money back if an investment goes down instead of up!
Regulated brokers are, however, subject to strict requirements and, in the UK, are regulated and authorised by the Financial Conduct Authority so everything is done by the book.
Forex.com scored best in our review of the top brokers for cannabis stocks , which takes into account 120+ factors across eight categories. Here are some areas where Forex.com scored highly in:
Forex.com offers one way to tradeForex . If you wanted to trade EURUSD
The two most important categories in our rating system are the cost of trading and the broker’s trust score. To calculate a broker’s trust score, we take into account a range of factors, including their regulation history, years in business, liquidity provider etc.
Forex.com have a AAA trust score . This is largely down to them being regulated by Financial Conduct Authority, segregating client funds, being segregating client funds, being established for over 19
|Regulated by||Financial Conduct Authority|
|Uses tier 1 banks|
|Segregates client funds|
Want to see how Forex.com? We’ve compared their spreads, features, and key information below.
|USD/JPY Spread||0.90||DAX Spread||250.0|
|FTSE 100 Spread||150.0|
|Platform||MT4, Web Trader, NinjaTrader, Tablet & Mobile apps|
|Base currency options||USD, GBP, EUR|
|Funding options||Bank transfer, Cheque, DebitCard,|